Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection.

IF 3 2区医学 Q1 PARASITOLOGY

Parasites & Vectors Pub Date : 2024-11-09 DOI:10.1186/s13071-024-06548-3

Juan Carlos Gabaldón-Figueira, Albert Ros-Lucas, Nieves Martínez-Peinado, Gavin Blackburn, Irene Losada-Galvan, Elizabeth Posada, Cristina Ballart, Elisa Escabia, Jordi Capellades, Oscar Yanes, María-Jesús Pinazo, Joaquim Gascón, Julio Alonso-Padilla

{"title":"Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection.","authors":"Juan Carlos Gabaldón-Figueira, Albert Ros-Lucas, Nieves Martínez-Peinado, Gavin Blackburn, Irene Losada-Galvan, Elizabeth Posada, Cristina Ballart, Elisa Escabia, Jordi Capellades, Oscar Yanes, María-Jesús Pinazo, Joaquim Gascón, Julio Alonso-Padilla","doi":"10.1186/s13071-024-06548-3","DOIUrl":null,"url":null,"abstract":"Background: Chagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic options. The infection is known to disrupt several host metabolic pathways, providing an opportunity for the identification of biomarkers.Methods: The metabolomic and lipidomic profiles of a cohort of symptomatic and asymptomatic patients with T. cruzi infection and a group of uninfected controls were analysed using liquid chromatography/mass spectrometry. Differences among all groups and changes before and after receiving anti-parasitic treatment across those with T. cruzi infection were explored.Results: Three lipids were found to differentiate between symptomatic and asymptomatic participants: 10-hydroxydecanoic acid and phosphatidylethanolamines PE(18:0/20:4) and PE(18:1/20:4). Additionally, sphinganine, 4-hydroxysphinganine, hexadecasphinganine, and other sphingolipids showed post-treatment abundance similar to that in non-infected controls.Conclusions: These molecules hold promise as potentially useful biomarkers for monitoring disease progression and treatment response in patients with chronic T. cruzi infection.","PeriodicalId":19793,"journal":{"name":"Parasites & Vectors","volume":"17 1","pages":"459"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549750/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parasites & Vectors","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13071-024-06548-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic options. The infection is known to disrupt several host metabolic pathways, providing an opportunity for the identification of biomarkers.

Methods: The metabolomic and lipidomic profiles of a cohort of symptomatic and asymptomatic patients with T. cruzi infection and a group of uninfected controls were analysed using liquid chromatography/mass spectrometry. Differences among all groups and changes before and after receiving anti-parasitic treatment across those with T. cruzi infection were explored.

Results: Three lipids were found to differentiate between symptomatic and asymptomatic participants: 10-hydroxydecanoic acid and phosphatidylethanolamines PE(18:0/20:4) and PE(18:1/20:4). Additionally, sphinganine, 4-hydroxysphinganine, hexadecasphinganine, and other sphingolipids showed post-treatment abundance similar to that in non-infected controls.

Conclusions: These molecules hold promise as potentially useful biomarkers for monitoring disease progression and treatment response in patients with chronic T. cruzi infection.

查看原文本刊更多论文

脂质丰度的变化与慢性克鲁斯锥虫感染的病情发展和治疗反应有关。

背景：恰加斯病由克鲁斯锥虫引起，是一种人畜共患疾病，影响到 700 多万人。目前对该疾病诊断的局限性阻碍了对患者预后和治疗效果的评估，从而延缓了新治疗方案的开发。已知感染会破坏宿主的几种代谢途径，这为鉴定生物标志物提供了机会：方法：采用液相色谱/质谱法分析了一组有症状和无症状的克鲁斯蝙蝠疫病感染者以及一组未感染的对照者的代谢组和脂质组谱。结果发现，有三种脂质可区分不同的 T. cruzi 感染者：结果：发现三种脂质可区分有症状和无症状的参与者：10-羟基癸酸、磷脂酰乙醇胺 PE(18:0/20:4) 和 PE(18:1/20:4)。此外，鞘磷脂、4-羟基鞘磷脂、十六碳鞘磷脂和其他鞘磷脂在治疗后的丰度与非感染对照组相似：这些分子有望成为监测慢性克鲁兹绦虫感染患者疾病进展和治疗反应的潜在有用生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Parasites & Vectors 医学-寄生虫学

CiteScore

6.30

自引率

9.40%

发文量

433

审稿时长

1.4 months

期刊介绍： Parasites & Vectors is an open access, peer-reviewed online journal dealing with the biology of parasites, parasitic diseases, intermediate hosts, vectors and vector-borne pathogens. Manuscripts published in this journal will be available to all worldwide, with no barriers to access, immediately following acceptance. However, authors retain the copyright of their material and may use it, or distribute it, as they wish. Manuscripts on all aspects of the basic and applied biology of parasites, intermediate hosts, vectors and vector-borne pathogens will be considered. In addition to the traditional and well-established areas of science in these fields, we also aim to provide a vehicle for publication of the rapidly developing resources and technology in parasite, intermediate host and vector genomics and their impacts on biological research. We are able to publish large datasets and extensive results, frequently associated with genomic and post-genomic technologies, which are not readily accommodated in traditional journals. Manuscripts addressing broader issues, for example economics, social sciences and global climate change in relation to parasites, vectors and disease control, are also welcomed.